Literature DB >> 9024720

An analysis of 8305 cases of carcinoid tumors.

I M Modlin1, A Sandor.   

Abstract

BACKGROUND: Carcinoid tumors are unusual and most reports are anecdotal or limited in number. A series of 2837 cases was published in 1975. No recent large series is available.
METHODS: The authors evaluated 5468 cases identified by the Surveillance, Epidemiology, and End Results (SEER) program of the National Cancer Institute (NCI) from 1973 to 1991 together with 2837 carcinoid cases previously registered by 2 earlier NCI programs. To the authors' knowledge, the 8305 carcinoid tumors analyzed represent the largest current epidemiology series to date.
RESULTS: The most frequent sites for carcinoids were the gastrointestinal (GI) tract (73.7%) and the bronchopulmonary system (25.1%). Within the GI tract, most occurred in the small bowel (28.7%), appendix (18.9%), and rectum (12.6%). For all sites, age-adjusted incidence rates were highest in African American males (2.12 per 100,000 population per year). Associated noncarcinoid tumors were frequent in conjunction with small intestinal (16.6%), appendiceal (14.6%), and colonic carcinoids (13.1%). The highest percentage of nonlocalized lesions were noted for pancreatic (76.1%), colonic (71.2%), and small intestinal carcinoids (70.7%) and this corresponded to their poor 5-year survival rates (34.1%, 41.6%, and 55.4%, respectively). The best 5-year survival rates were recorded for appendiceal (85.9%), bronchopulmonary (76.6%), and rectal carcinoids (72.2%). These exhibited invasive growth or metastatic spread in only 35.4%, 27.2%, and 14.2% of cases, respectively.
CONCLUSIONS: Carcinoids appear to have increased in incidence in the past 20 years. In part, this may be due to different surgical rules of the various registries, improved diagnostic technology, and increased awareness. A cumulative analysis of all types of carcinoid tumors in the SEER group indicates that in 45.3% metastases are already evident at the time of diagnosis. The overall 5-year survival rate of all carcinoid tumors regardless of site was 50.4% +/- 6.4%.

Entities:  

Mesh:

Year:  1997        PMID: 9024720     DOI: 10.1002/(sici)1097-0142(19970215)79:4<813::aid-cncr19>3.0.co;2-2

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  258 in total

1.  Prevalence of Small Intestine Carcinoid Tumors: A US Population-Based Study 2012-2017.

Authors:  Mohannad Abou Saleh; Emad Mansoor; Mohammad Anindo; Gerard Isenberg
Journal:  Dig Dis Sci       Date:  2018-12-05       Impact factor: 3.199

2.  Management and disease outcome of type I gastric neuroendocrine tumors: the Mount Sinai experience.

Authors:  William C Chen; Richard R P Warner; Stephen C Ward; Noam Harpaz; Celia M Divino; Steven H Itzkowitz; Michelle K Kim
Journal:  Dig Dis Sci       Date:  2014-11-16       Impact factor: 3.199

Review 3.  The diversity and commonalities of gastroenteropancreatic neuroendocrine tumors.

Authors:  Simon Schimmack; Bernhard Svejda; Benjamin Lawrence; Mark Kidd; Irvin M Modlin
Journal:  Langenbecks Arch Surg       Date:  2011-01-28       Impact factor: 3.445

4.  Ovarian tumor-associated carcinoid heart disease presenting as severe tricuspid regurgitation.

Authors:  Hong-Won Shin; Hyungseop Kim; Hyuck-Jun Yoon; Hyoung-Seob Park; Yun-Kyeong Cho; Chang-Wook Nam; Seung-Ho Hur; Yoon-Nyun Kim; Kwon-Bae Kim
Journal:  J Cardiovasc Ultrasound       Date:  2011-03-31

5.  Primary carcinoid tumour of the pancreas.

Authors:  José Alejandro Pérez-Fidalgo; Amparo Oltra Ferrando; Antonio López Jiménez; Inmaculada Maestu Maiques
Journal:  Clin Transl Oncol       Date:  2006-01       Impact factor: 3.405

6.  Multiple microcarcinoids in a patient with long standing ulcerative colitis.

Authors:  T Matsumoto; Y Jo; R Mibu; M Hirahashi; T Yao; M Iida
Journal:  J Clin Pathol       Date:  2003-12       Impact factor: 3.411

7.  Surveillance strategy for rectal neuroendocrine tumors according to recurrence risk stratification.

Authors:  Dong Hyun Kim; Jin Ha Lee; Yoon Jin Cha; Soo Jung Park; Jae Hee Cheon; Tae Il Kim; Hoguen Kim; Won Ho Kim; Sung Pil Hong
Journal:  Dig Dis Sci       Date:  2013-12-10       Impact factor: 3.199

8.  [CGH findings in neuroendocrine tumours of the lung].

Authors:  G Johnen; M Krismann; M Jaworska; K-M Müller
Journal:  Pathologe       Date:  2003-05-15       Impact factor: 1.011

Review 9.  Intra-arterial liver-directed therapies for neuroendocrine hepatic metastases.

Authors:  Sanjay Gupta
Journal:  Semin Intervent Radiol       Date:  2013-03       Impact factor: 1.513

Review 10.  Cutaneous metastases as an initial manifestation of visceral well-differentiated neuroendocrine tumor: a report of four cases and a review of literature.

Authors:  Jaroslaw Jedrych; Klaus Busam; David S Klimstra; Melissa Pulitzer
Journal:  J Cutan Pathol       Date:  2013-12-03       Impact factor: 1.587

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.